| EBITDA Margin: guided vs achieved | 21.60% achieved Guided 20.00%–22.00% |
|---|---|
| Management target | Revenue 18.0% 2032 |
| Revenue growth | 19.5% YoY growth in Q1 FY27. |
|---|---|
| Margins | EBITDA margins expanded 530 bps YoY to 21.6%. |
| Demand visibility | Strong traction in API orders returning after June lag. |
| Management confidence | High; integration complete, balance sheet strongest in history. |
Growth
Revenue grew 19.5% YoY to ₹946 Cr; EBITDA rose 59% to ₹205 Cr. PAT doubled to ₹79 Cr.
Outlook
Guided 18% CAGR to reach $1B by 2032; ₹250-300 Cr annual capex; BioForLife acquisition closing in FY27.
Risks
API volatility due to raw material price fluctuations and ongoing geopolitical conflicts; long gestation for oncology pipeline.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 19.5% (= BEAT)
- Guided ~20% EBITDA margin → delivered 21.6% (= BEAT)
- Guided ₹50-60Cr synergy accrual → delivered ₹60Cr annualized (= BEAT)
Partly delivered
- Guided 26-27% tax rate → delivered 27% (on track = PARTIAL)
- Guided ₹1,000Cr EBITDA target → achieved ₹820Cr annualized run-rate (= PARTIAL)
Investor Presentation filed with BSE, NSE: VIYASH. Summary written with AI assistance from the document.
Viyash Scientific Ltd: key numbers
- Share price
- ₹244.35
- Market cap
- ₹10,791 Cr
- Revenue (annual)
- ₹3,420 Cr
- Net profit (annual)
- ₹177.3 Cr
- P/E (TTM)
- 63.0×Sector 50.4×
- Promoter holding
- 61.31%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Viyash Scientific Ltd
All →Viyash Scientific Employee Stock Options
Viyash Scientific allotted 1,107,309 ESOP shares at exercise prices of ₹86 and ₹101. Paid-up capital rose to ₹88.33 Crore post-allotment.
Viyash Scientific Merger & Restructuring
Viyash Scientific Limited announced receipt of Italian regulatory approval for its subsidiary Alivira Animal Health's acquisition of BioForLife Italia S.r.l. The transaction completion timeline is extended.
Viyash Scientific Acquisition
Viyash Scientific Limited received Italian regulatory approval for its proposed 100% acquisition of BioForLife Italia S.r.l., with the completion timeline now extended by two months.
Viyash Scientific Employee Stock Options
Viyash Scientific Limited allotted 6,12,773 equity shares following the exercise of options under its ESOP 2020 and 2026 schemes. The company's paid-up capital increased to Rs. 88.10 Crore.
Viyash Scientific Earnings Call Transcript: Key Takeaways
Viyash reports a robust Q1FY27 with 20% revenue growth and significantly expanded EBITDA margins at 21.6%. The company is essentially net-debt free following successful integration and is pivoting toward high-potent oncology products.
- Call
- Guides 18% growth
Viyash Scientific Investor Presentation: Key Takeaways
Viyash Scientific reported strong Q1 FY27 results with 19.5% YoY revenue growth and 59.2% EBITDA growth, driven by integration success and operational leverage.